𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

✍ Scribed by Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M.M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.

Book ID
118239608
Publisher
Massachusetts Medical Society
Year
2011
Tongue
English
Weight
609 KB
Volume
364
Category
Article
ISSN
0096-6762

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Combined BRAF and MEK Inhibition in Mela
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri πŸ“‚ Article πŸ“… 2012 πŸ› Massachusetts Medical Society 🌐 English βš– 528 KB

## Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with da braf e nib, a selective BRAF inhibitor, and trametinib, a